MJGCF

Tag: MJGCF

(THLD, NOV, AMP, MJGCF, FMBI) Stock Highlights by PennyOTCStock.com

Posted by Steve Stock on February 4th, 2012

Threshold Pharmaceuticals, Inc (NASDAQ:THLD) was founded in 2001 and is headquartered in Redwood City, California. Threshold Pharmaceuticals has a license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals.

Tags:

NOV, AMP, FMBI, THLD, MJGCF

(THLD, PZN, TEN, MJGCF, EBMT) Featured Stocks by PennyGovernance.com

Posted by pennygovernance on February 4th, 2012

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) has a license agreement with Eleison Pharmaceuticals, Inc. to develop and commercialize glufosfamide for the treatment of cancer in humans and animals. Threshold Pharmaceuticals, a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer.

Tags:

EBMT, THLD, PZN, TEN, MJGCF

(THLD, CYH, DEJ, MJGCF, TLR) Notable Stock by PennyOmega.com

Posted by pennylynnomega on February 4th, 2012

Tags:

DEJ, THLD, TLR, CYH, MJGCF

(THLD, RTN, RDY, MJGCF, WGL) Stocks in Review by DoubleInStocks.com

Posted by doubleinstocks1 on February 4th, 2012

Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) recently announced that a global agreement was signed with Merck KGaA, Darmstadt, Germany, to co-develop and commercialize TH-302, Threshold Pharmaceuticals' small molecule hypoxia-targeted drug.

Tags:

rtn, RDY, WGL, THLD, MJGCF

(THLD, FCN, MDT, MJGCF, MKL) Stocks in Review by CRWEPicks.Com

Posted by stockrider on February 4th, 2012

Threshold Pharmaceuticals, Inc (NASDAQ:THLD) is also eligible to receive a $20 million milestone payment based on positive results from its randomized Phase 2 trial in pancreatic cancer. Total potential milestone payments are $525 million, comprised of $280 million in regulatory and development milestones and $245 million in sales-based milestones.